Keros Therapeutics (KROS) Current Deferred Revenue (2025)

Keros Therapeutics (KROS) reported Current Deferred Revenue of $155000.0 for Q3 2025, down 83.24% quarter-over-quarter from $925000.0 in Q2 2025.

Keros Therapeutics (KROS) Current Deferred Revenue (2025) Analysis & Trends

Keros Therapeutics has reported Current Deferred Revenue for 1 years, with the latest figure at $155000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Keros Therapeutics	372.58 Mn	85.18 Mn	-

Download Data